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Our laboratories first reported on two novel classes of
complex synthetic lipids (alkylamidopropyl or alkylthio-
glycerol phosphocholines and phosphate ester-linked
lipid–AZT conjugates) that have selective and potent
activity against infectious human immunodeficiency virus
(HIV) replication and pathogenesis in vitro. These
compounds have a unique site of action involving alteration
of HIV gp160/gp120 activity and production of defective
virus particles (Kucera et al., 1990a,b; Meyer et al., 1991;
Piantadosi et al., 1991; Krugner-Higby et al., 1995). A
thiolipid–nucleotide conjugate (BM21-1290) has recently
been introduced into Phase I/II tolerability and efficacy
trials in ARC/AIDS patients by Boehringer Mannheim
(Herrmann DBJ, Schleger C & Opitz HG; Antiretroviral
activity of the novel candidate anti-AIDS drug
BM21.1290 in the Friend-virus leukemia system in vivo;
VIth German AIDS Congress, October 24–26 1997,
Munich, Germany, Abstract V160; Herrmann DBJ, Opitz
HG & Kucera LS; BM21-1290: evaluation of the anti-
retroviral activity of a new anti-AIDS drug in-vivo. IVth
Conference on Retroviruses and Opportunistic Infections,
January 22–26 1997, Washington, DC, USA, Abstract
p92). Among the reported alkylamidopropyl phospho-
choline (PC lipid) analogues synthesized and tested for
anti-HIV-1 activity, the most selective was compound CP-
51, 1-octadecanamido-2-ethoxypropyl-3-phosphocholine
(Kucera et al., 1990a). In order to extend these observa-
tions, we synthesized a series of CP-51 analogues to
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Our laboratories first reported two novel classes
of complex synthetic lipids, including alkylami-
dophosphocholines (PC lipid; CP-51) and
alkylamidophosphate ester-linked lipid–AZT
conjugates (lipid–AZT conjugates; CP-92), with
selective and potent activity against human
immunodeficiency virus type 1 (HIV-1). To extend
these observations, we synthesized additional PC
lipids and lipid–AZT conjugates (INK and INK–AZT
conjugate) to evaluate their structure–activity
relationships by testing for selectivity against
infectious wild-type (wt) and drug-resistant HIV-1
replication, virus fusogenic activity and toxicity
for mouse bone marrow cells. PC lipid compounds
with medium chain lengths at positions 1 and 2
gave an improved selective index (SI). INK-3, with
12 and 8 carbons and INK-15, with 10 and 12
carbons were among the most selective when
evaluated in CEM-SS cells. INK-14, a lipid–AZT
conjugate where AZT replaced the choline in PC
lipid INK-3, gave the highest SI of >1250 against
both infectious wt HIV-1 replication in CEM-SS
cells and a clinical isolate in peripheral blood
leukocytes. Notably, the PC lipid compounds INK-3
and INK-15, but not the lipid–AZT conjugate INK-
14, were potent inhibitors of matched pairs of
AZT-sensitive and AZT-resistant HIV-1 clinical
isolates. INK-3 also inhibited replication of HIV-2
and TIBO-resistant HIV-1, and inhibited HIV-1-
mediated fusogenic activity by 78, 41 and 9% in a
dose-dependent manner. The TC50 for mouse bone
marrow cells was >100 µg/ml for INK-3 compared
to 9.15–14.17 µg/ml for CP-51 and 0.142–0.259
µg/ml for AZT. These data suggest that optimum
PC lipid compounds are significantly less toxic
than AZT and have high potential as novel thera-
peutic agents for AIDS.
Keywords: alkylamidophosphocholine; phospho-
lipid–nucleoside conjugate; HIV-1; AIDS
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evaluate their structure–activity relationships and thus to
optimize the PC lipid compound for future evaluation as a
potential therapeutic agent for AIDS. Results of this inves-
tigation indicated that among the PC lipid compounds
tested in CEM-SS cells, compounds INK-3 and INK-15
with intermediate hydrocarbon chain lengths of 12 and 10,
respectively, at position 1, and of 8 and 12, respectively, at
position 2, gave the highest selectivity index (SI) against
infectious HIV-1 replication. Selected PC lipid
compounds were active against AZT-resistant clinical
isolates, TIBO-resistant HIV-1 and wild-type HIV-2,
inhibited HIV-1 fusogenic activity, and were less toxic to
mouse bone marrow cells compared to AZT. Based on
these interesting results, optimum PC lipid compounds
may have great potential as novel therapeutic agents for
AIDS, either alone or in combination therapy.
Materials and Methods: Chemistry
All chemicals were used as provided by the supplier
without further purification unless otherwise indicated.
AZT was obtained from Boehringer Mannheim
(Mannheim, Germany). Column chromatography was
performed with silica gel 60 (230–400 or 70–230 mesh).
Melting points were obtained on a Hoover Meltemp appa-
ratus and are uncorrected. Proton NMR spectra were
obtained on Bruker 300 MHz or Varian 400 MHz spec-
trometer as solutions in CDCl3 with Me4Si as an internal
standard. The final compounds were, in general, hygro-
scopic solids. FAB mass spectra were run on a VG 70S
mass spectrometer. Thin layer chromatography (TLC) of
phosphocholines in CHCl3 : MeOH : NH4OH (70 : 35 :
7) and CHCl3 : MeOH (2 : 1) gave a single spot, which
gave a blue colour with a modified Dittmer–Lester reagent
(Ryu & MacCoss, 1979). A representative synthetic proce-
dure is given for INK-3; the remaining phosphocholines
were prepared from the appropriate reagents using analo-
gous procedures as those detailed below and in our previous
papers (Piantadosi et al., 1991; Meyer et al., 1991; Morris-
Natschke et al., 1993). Complete high resolution mass
spectra results are available as supplementary data from the
Editor-in-Chief.
3-Dodecanamido-1,2-propanediol
3-Amino-1,2-propanediol (42 g, 0.47 mol) was dissolved
in pyridine (150 ml) and DMF (200 ml). Dodecanoyl chlo-
ride (47 g, 0.46 mol) in 150 ml DMF was added dropwise.
After 24 h at room temperature, the product was removed
by filtration, washed with H2O and recrystallized from
MeOH, then from CHCl3. The amide was obtained in
28% yield (34.7 g, 0.013 mol, m.p. 94–96°C). 1H NMR
(CDCl3): 0.90 (t, 3H, terminal CH3), 1.25 [m, 16H
(CH2)8], 1.6 (m, 2H, NHCOCH2CH2), 2.25 (t, 2H,
NHCOCH2), 3.45 (m, 2H, CH2NH), 3.6 (m, 2H,
CH2OH), 3.8 (m, 1H, CHOH), 5.8 (t, 1H, NH).
3-Dodecanamido-1-triphenylmethoxy-2-
propanol
The above diol (5.5 g, 0.020 mol) was dissolved in dry pyri-
dine (50 ml), then a solution of trityl chloride (5.6 g, 0.020
mol) in pyridine (50 ml) was added dropwise at 50°C. The
reaction mixture was stirred at this temperature for 10 h
and then cooled. The pyridine was removed under vacuum,
and water (100 ml) was added to the solid residue. After
filtration and washing, the crude product was partitioned
between water and CHCl3. The water layer was extracted
again with CHCl3 and the organic layers combined and
dried over anhydrous Na2SO4. After removing solvent, the
resulting solid was dissolved in hexane : ethyl acetate (3 :
1); 1 g of starting diol was filtered. The mother liquor was
concentrated and chromatographed on silica gel with a
discontinuous gradient of hexane : EtOAc to give 7 g
(0.014 mol, 70% yield) of pure product. 1H NMR
(CDCl3): 0.90 (t, 3H, terminal CH3), 1.25 [m, 16H
(CH2)8], 1.6 (m, 2H, NHCOCH2CH2), 2.2 (t, 2H,
NHCOCH2), 3.2–3.4 (overlapping m, 3H, CH2NH and
CHaCHbOTr), 3.55 (m, 1H, CHaCHbTr) 3.9 (m, 1H,
CHOH), 5.7 (t, 1H, NH), 7.3–7.5 (m, 15H, aromatic H).
3-Dodecanamido-2-octyloxy-1-triphenyl-
methoxypropane
The synthesized trityl ether (7.0 g, 0.013 mol) in 30 ml dry
THF was added dropwise to an ice-cooled suspension of
sodium hydride (1.0 g of 60% oil dispersion, 0.025 mol) in
100 ml THF under nitrogen. After warming to room
temperature, heat was applied (60°C) for 1 h. 1-
Bromooctane (2.9 g, 0.015 mol, neat) was added dropwise
and heating continued for 10 h. After cooling, ice and then
water were added slowly. The biphasic system was sepa-
rated and the water layer extracted with EtOAc (3×50 ml).
All organic fractions were combined and dried over anhy-
drous Na2SO4. After removing solvent in vacuo, the residue
was chromatographed with a gradient of hexane : EtOAc
(100 : 0 to 6 : 1) to give 3.6 g (38% yield) of pure product.
Impure product was rechromatographed using the same
conditions to give an added 3.0 g (31% yield) of product as
a viscous oil. 1H NMR (CDCl3): 0.85 (t, 6H, terminal
CH3), 1.25 [m, 26H (CH2)8 and (CH2)5], 1.45 (m, 4H,
NHCOCH2CH2 and OCH2CH2), 2.2 (t, 2H,
NHCOCH2), 3.2–3.6 (overlapping m, 7H, CH2CHCH2,
OCH2), 5.75 (t, 1H, NH), 7.3–7.5 (m, 15H, aromatic H).
3-Dodecanamido-2-octyloxy-1-propanol
Detritylation of the above compound (6.0 g, 9.5 mmol) was
accomplished using p-toluenesulphonic acid (0.6 g, 3.1
mmol) in CHCl3 : MeOH (60 ml : 18 ml). The reaction
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mixture was stirred at room temperature for 24 h then satu-
rated NaHCO3 solution was added and stirred for 30 min.
The layers were separated and the CHCl3 fraction dried
over anhydrous Na2SO4. After concentration in vacuo, the
residue was purified twice by column chromatography
using CHCl3 : MeOH as eluent (100 : 0 and 15 : 1) to give
3.0 g (80% yield) of pure 3-dodecanamido-2-octyloxy-1-
propanol (m.p. 42–43°C). 1H NMR (CDCl3): 0.9 (t, 6H,
terminal CH3), 1.25 [m, 26H (CH2)8 and (CH2)5], 1.6 (m,
4H, NHCOCH2CH2 and OCH2CH2), 2.2 (t, 2H,
NHCOCH2), 3.2–3.7 (overlapping m, 7H, CH2CHCH2,
OCH2), 5.75 (t, 1H, NH).
3-Dodecanamido-2-octyloxypropyl 2-bromo-
ethyl phosphate
3-Dodecanamido-2-octyloxy-1-propanol (1.0 g, 2.6 mmol)
in 60 ml 2 : 1 anhydrous Et2O : THF was cooled to 0°C.
Pyridine (3.3 g) then 2-bromoethyl dichlorophosphate (2.4
g, 0.010 mol, prepared as described by Hansen et al., 1992)
were added dropwise. After warming to room temperature,
the mixture was refluxed for 4 h, cooled and water (10 ml)
added. After stirring for 30 min, the solvent was removed in
vacuo and the residue dissolved in 100 ml CHCl3 : MeOH
(2 : 1). The solution was extracted with water and back-
extracted with 2×50 ml 2 : 1 CHCl3 : MeOH. The
combined organic fractions were dried over anhydrous
Na2SO4, evaporated and chromatographed on silica gel
using a gradient of CHCl3 : MeOH (100 : 1 to 15 : 1). The
desired bromoethylphosphate (633 mg, 1.1 mmol) was
obtained in 43% yield. 1H NMR (CDCl3): 0.85 (t, 6H,
terminal CH3), 1.25 [m, 26H (CH2)8 and (CH2)5], 1.55 (m,
4H, NHCOCH2CH2 and OCH2CH2), 2.3 (t, 2H,
COCH2), 3.4–3.7 (overlapping m, 7H, CHCH2NHCO,
CH2Br, OCH2), 3.85 and 4.25 (two m, 4H,
CH2OPO3CH2), 6.8 (m, 1H, NH).
3-Dodecanamido-2-octyloxypropyl phospho-
choline (INK-3)
The above phosphate ester (633 mg, 1.1 mmol) in 52 ml
CHCl3 : isopropanol : DMF (5 : 3 : 5) was reacted with
aqueous Me3N (7.6 ml) at 65°C for 5 h. After cooling,
Ag2CO3 (380 mg) was added and the heat reapplied for 1
h. After filtering the precipitated AgBr, the solvent was
removed in vacuo and the residue purified by chromatog-
raphy on silica gel using CHCl3 : MeOH (10 : 1 to 2 : 1)
followed by CHCl3 : MeOH : NH4OH (75 : 25 : 5) to
give 275 mg pure (46% yield) and 140 mg impure phos-
phocholine. FAB MS showed a [MH]+ ion at 551.418345
(C28H60N2O9P, 1.0 p.p.m.). 1H NMR (CDCl3): 0.87 (t,
6H, terminal CH3), 1.25 [m, 26H (CH2)8 (CH2)5], 1.5 (m,
4H, NHCOCH2CH2, OCH2CH2), 2.2 (t, 2H, COCH2),
3.3 [s, 9H, N(CH3)3], 3.3–3.8 (overlapping m, 5H,
CH2CHOCH2) (3.8–3.9, overlapping m, 4H, CH2OP,
CH2NMe3), 4.4 (m, 2H, PO3CH2), 7.0 (m, 1H, NH).
3-Dodecanamido-2-octyloxypropyl diphenyl
phosphate
Diphenylchlorophosphate (0.4 ml, 1.7 mmol) in 10 ml
diethyl ether was cooled to 4°C under nitrogen. 3-
Dodecanamido-2-octyloxy-1-propanol (500 mg, 1.3 mmol)
in 8 ml pyridine and 10 ml Et2O was added dropwise. The
solution was warmed to room temperature, then heated to
around 52°C for 4 h and cooled to room temperature, diluted
with 30 ml Et2O, washed with 15 ml portions of water, 0.5
M HCl and water. The organic layer was dried over anhy-
drous Na2SO4, filtered and concentrated in vacuo to an oil.
Chromatography with a gradient of hexane : EtOAc (10 : 1
to 3 : 1) gave 556 mg (0.9 mmol, 69%) of pure product. 1H
NMR (CDCl3): 0.9 (t, 6H, terminal CH3), 1.25 [m, 26H
(CH2)8 and (CH2)5], 1.55 (m, 4H, NHCOCH2CH2 and
OCH2CH2), 2.3 (t, 2H, COCH2), 3.3–3.7 (overlapping m,
5H, OCH2, CHCH2NHCO), 4.25 (m, 2H, CH2OP), 5.9
(m, 1H, NH), 7.2–7.8 (m, 10H, aromatic H).
3-Dodecanamido-2-octyloxypropyl phosphatidic
acid
PtO2 (81 mg) was placed in a Parr hydrogenation bottle. 3-
Dodecanamido-2-octyloxypropyl diphenyl phosphate (589
mg, 1.0 mmol) in 118 ml EtOH was then added. After
hydrogenation at 158.5 kPa (23 p.s.i.) for 4.5 h, the reac-
tion mixture was filtered and checked for completion by
TLC. To ensure complete conversion to the phosphatidic
acid, hydrogenation was continued for another 6 h using
120 mg of fresh catalyst. The reaction mixture was then
filtered through Celite and the EtOH removed in vacuo.
The residue was chromatographed on silica gel using 4 : 1
CHCl3 : MeOH as eluent to obtain 233 mg (0.54 mmol,
54% yield) of pure phosphatidic acid. 1H NMR (CDCl3):
0.9 (t, 6H, terminal CH3), 1.25 [m, 26H (CH2)8 and
(CH2)5], 1.55 (m, 4H, NHCOCH2CH2 and OCH2CH2),
2.3 (t, 2H, COCH2), 3.3–3.7 (overlapping m, 5H, OCH2,
CHCH2NHCO), 4.0 (m, 2H, CH2OP), 6.8 (m, 1H, NH).
3′-Azido-3′-deoxy-5′-(3-dodecanamido-2-octyl-
oxypropyl)-phosphothymidine (INK-14)
The procedure of Piantadosi et al. (1991) was followed to
synthesize INK-14 in 22% yield from the above phospha-
tidic acid and AZT. FAB MS showed a [MH+Na]+ ion at
737.403800 (C33H59N6O9PNa, –8.0 p.p.m.). 1H NMR
(CDCl3): 0.9 (t, 6H, terminal CH3), 1.25 [m, 26H (CH2)8
and (CH2)5], 1.55 (m, 4H, NHCOCH2CH2 and
OCH2CH2), 1.8 (s, 3H, thymine CH3), 2.2 (t, 2H,
COCH2), 2.3–2.55 (m, 2H, 2′-CH2), 3.3–3.6 (overlapping
m, 5H, OCH2, CHCH2NHCO), 3.8–4.2 (overlapping m,
5H, CH2OPO3CH2, 4′-CH), 4.5 (1H, 3′-CH), 6.15 (m,
1′-CH), 7.4 (m, 1H, thymine CH).
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Materials and Methods: Virology
Virus stocks
HIV-1 (strain IIIB) was propagated in H9IIIB cells as
previously described (Krugner-Higby et al., 1995). Stocks
of HIV-2 from R Weiss (Institute of Cancer Research,
London, UK), TIBO-resistant HIV-1 (RT mutant at
codons 103 and 181) from E Emini (Merck, Sharp &
Dohme Research Laboratories, West Point, Pa., USA) and
AZT-resistant HIV-1 isolates 1073 (RT mutant at codons
70 and 215) and 1074 (RT mutant at codons 70 and 215),
and matched pairs of AZT-sensitive and AZT-resistant
HIV-1 clinical isolates G-762 (wild-type), G-691 (RT
mutant) and H112-2 (wild-type), G-910 (RT mutant at
codon 215) from D Richman (University of California, La
Jolla, Calif., USA) were obtained through the AIDS
Research and Reference Reagent Program (Division of
AIDS Program, NIH, Bethesda, Md., USA). Stocks of
viruses were propagated in acutely infected CEM-SS cells
as previously described (Krugner-Higby et al., 1995).
Cell cultures
All primary peripheral blood leukocytes (PBL) and cell
lines were incubated and maintained in RPMI 1640
medium supplemented with penicillin (100 U/ml), strepto-
mycin (100 µg/ml), 2 mM L-glutamine and 20% fetal
bovine serum (growth medium) as previously described
(Krugner-Higby et al., 1995). PBL were obtained from
HIV-1-seronegative male and female personnel in the
laboratory. Whole blood was separated into PBL using
Isolymph (Gallard-Schlesinger Industries, Carle Place,
N.Y., USA) according to a protocol supplied by the manu-
facturer. The separated PBL were activated for 3 days in the
presence of phytohaemagglutinin (PHA; 5 µg/ml in
growth medium), washed in growth medium, treated with
polybrene (5 µg/ml in growth medium) and infected with
HIV-1 in the presence of polybrene (1 µg/ml in growth
medium). After a 2 h virus attachment, the cells were
washed with growth medium to remove unattached HIV-
1 and incubated (1×106 cells/ml of growth medium) for 96
h with or without added test compounds. Supernatant
medium was harvested to measure virus replication by
reverse transcriptase (RT) activity (Krugner-Higby et al.,
1995).
TC50 determinations
To measure the cytotoxicity in CEM-SS cells, test
compounds were dissolved in 95% ethanol, methanol :
chloroform (1 : 1) or RPMI 1640 plus 20% FBS growth
medium, diluted in log10 or 0.5 log10 series in growth
medium and tested for cytotoxicity in triplicate wells
containing 10 000 CEM-SS cells/well of a 96-well plate. A
viable cell count was made prior to the test to ensure more
than 90% cell viability. Log phase cells were treated with
test compound for 48 h at 37°C (approximately 2.5 cell
generations in untreated control cultures) and pulse-
labelled with 1 µCi [3H]TdR (sp. act. 20 Ci/mmol) for 6 h
before harvesting the cells using a multichannel cell
harvester to measure total DNA synthesis in the presence
or absence of compound. To measure cytotoxicity in PBL,
the cells were activated with PHA (5 µg/ml) for 72 h,
washed to remove the PHA and 20 000 activated PBL
cells/well were cultured for 96 h in growth medium with or
without test compound as described for CEM-SS cells.
The treated PBL cells were labelled with 0.1 µCi [3H]TdR
(sp. act. 20 Ci/mmol) during the final 24 h culture period
before harvesting. From the data, a TC50 for cytotoxicity
was calculated as previously described by Chou and
coworkers (Chou & Talalay, 1987; Johnson et al., 1989)   as
cited by Piantadosi et al. (1991).
Syncytium plaque assay
The syncytium plaque assay for infectious virus multiplica-
tion was done in the presence or absence of PC lipid or
lipid–AZT conjugate as previously described by us (Kucera
et al., 1990a). The syncytium plaques were counted on day
5 or 6 post-infection and treatment and the percentage
inhibition and effective concentration50 (EC50) were calcu-
lated by the method of Chou and coworkers (Chou &
Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et
al. (1991).
Fusogenic assay
Persistently HIV-1-infected H9IIIB cells were treated with
compound for 96 h and cocultured with uninfected CD4+
CEM-SS cells (ratio 1 : 100) in the presence of added
compound for 48 h. The number of fusogenic cells was
counted relative to untreated control cells to determine the
percentage inhibition of fusogenic cells. The EC50 values
were calculated by the method cited by Piantadosi et al.
(1991).
Colony forming units–granulocyte macrophage
(CFU-GM) assay
Mouse bone marrow granulocyte/macrophage cells were
harvested and suspended in soft agar medium with or
without added test compound (Herrmann DBJ, Kucera
LS, Zilch H, Mertens A & Opitz HG; BM21.1290: in-
vitro evaluation of a potential new anti-AIDS compound;
XIth International Conference on AIDS, July 7–12 1996,
Vancouver, Canada, Abstract p64). After incubation, the
number of cell colonies was counted to determine the
percentage inhibition of colony formation relative to a
mock (PBS)-treated control. The 50% toxic concentration
(TC50) was calculated by the method cited by Piantadosi et
al. (1991).
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Results
Chemistry
Phospholipid and lipid–AZT conjugates were synthesized
in our laboratories as previously described (Piantadosi et al.,
1991). Briefly, 3-amino-1,2-propanediol was reacted with
an acyl chloride to form an alkylamidopropanediol. The
primary alcohol was protected as the trityl ether by reaction
with trityl chloride, then the secondary alcohol was alky-
lated with the appropriate alkyl halide using sodium
hydride as the base. After removing the trityl ether with p-
toluenesulphonic acid, the hydroxy group was converted
either to a phosphocholine [reaction first with bromoethyl
phosphodichloridate (Hansen et al., 1982) then with
aqueous trimethyl amine] or, in the case of INK-14, to the
phosphatidic acid (reaction with diphenyl chlorophosphate
then catalytic hydrogenolysis over PtO2). The phosphatidic
acid was coupled with AZT using dicyclohexylphosphodi-
imide as the condensing agent.
Evaluation of compounds for cytotoxicity and
anti-HIV-1 activity
To optimize the activity and/or SI, PC lipid and
lipid–AZT conjugate compounds varying in hydrocarbon
chain lengths at position 1 or 2 were synthesized (Table 1)
and evaluated for cytotoxicity, anti-HIV-1 activity and SI
in CEM-SS and PBL cells. Results of these experiments
(Table 2) using CEM-SS cells indicated that the TC50
ranged from 27.6 (INK-2) to >100 µM (INK-13 and -14).
The EC50 ranged from <0.08 (INK-14) to 1.02 µM (INK-
8). The SI ranged from 53.2 (INK-8) to >1250 (INK-14)
(Table 2). Compounds with a 12 or 10 carbon chain length
at position 1, an 8 or 12 carbon chain length at position 2,
and phosphocholine at position 3 of the three carbon back-
bone (INK-3 or INK-15) gave the highest SI (298.9 and
389.0, respectively) among the PC lipid compounds. INK-
14, which has the same hydrocarbon chain lengths at
position 1 and position 2 as INK-3 but is linked at position
3 through a phosphate ester bond to AZT in place of phos-
phocholine (see Table 1), gave the highest SI (>1250)
Alkylamidophospholipids as anti-HIV-1 agents
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Table 1. Chemical structures of synthetic 
phospholipids
Compound A B C D*
CP-51 NHCO 16 1 PC
INK-1 NHCO 10 11 PC
INK-2 NHCO 10 9 PC
INK-3 NHCO 10 7 PC
INK-4 O 11 9 PC
INK-6 NHCO 10 5 PC
INK-7 NHCO 16 7 PC
INK-8 NHCO 10 7 OPO3(CH2)3N(CH3)3
INK-13 NHCO 8 7 PC
INK-14 NHCO 10 7 OPO3AZT





Table 2. Evaluation of PC lipid and lipid–AZT conjugate compounds for cell cytotoxicity, anti-HIV-1 activity and
SI in CEM-SS and PBL cells*
TC50 (µM)† EC50 (µM)† SI‡
Compound CEM-SS PBL CEM-SS PBL CEM-SS PBL
INK-1 30.3±8.9 43.7 0.47±0.2 1.25 64.5 34.9
INK-2 27.6+5.7 48.4 0.15±0.1 >3 184.0 <16.1
INK-3 56.8±22.4 >50 0.19±0.1 >3 298.9 ~16.7
INK-4 75.7±21.7 48.2 0.64±0.4 >3 118.3 <16.1
INK-6 40.2±12.8 >50 0.21±0.1 0.63 191.4 >79.4
INK-7 36.0 31.6 0.67 1.5 53.7 21.0
INK-8 54.3±14.3 >50 1.02±0.3 >3 53.2 ~16.7
INK-13 >100±0.0 >50 0.77±0.7 2.5 >129.9 >20.0
INK-14 >100±0.0 >50 <0.08±0.08 0.62 >1250 >80.6
INK-15 38.9±2.9 42.1 0.10±0.06 >3 389.0 <14.0
CP-51§ 14.3±2.3 ND 0.11±0.06 ND 130 –
AZT§ 3.7±1.6 ND 0.009±0.008 ND 411 –
*The TC50 (cytotoxicity) and EC50 (anti-HIV-1 activity) data from CEM-SS cells represent averages ±SD of 2–4 independent experiments per
compound except for compound INK 7, which was tested once. Data from PBL cells were from a single independent experiment. To deter-
mine the TC50, five serial concentrations of each compound were assayed in triplicate for [
3H]TdR incorporation into total DNA. To determine
the EC50, three to five serial concentrations of each compound were assayed in duplicate. The syncytial plaque assay was used with CEM-SS
cells infected with the prototype of HIV-1 (strain H9IIIB). A reverse transcriptase assay was used with PBL cells infected with a clinical isolate
of HIV-1 (strain H112-2) as cited in Kucera et al. (1990a).
†TC50 and EC50 values were calculated by the method of Chou and coworkers (Chou & Talalay, 1987; Johnson et al., 1989) as cited by
Piantadosi et al. (1991).
‡SI is the ratio TC50/EC50.
§Data from Piantadosi et al. (1991).
among all the compounds evaluated. In PBL cells, the TC50
values were comparable to those from CEM-SS cells.
However, the EC50 values were consistently higher in PBL
than in CEM-SS cells (Table 2). These results were most
likely due to differences in sensitivity of prototype HIV-1
(strain H9IIIB) and a clinical isolate (strain H112-2) to the
test compounds.
Inhibition of HIV-2 and TIBO- and AZT-resistant
HIV-1 strains as measured by syncytial plaque
assay
Since selected PC lipid compounds (for example INK-3
and CP-51) have potent activity against prototype strains
of HIV-1, we extended evaluation of their activity against
HIV-2 and TIBO- and AZT-resistant HIV-1 clinical
isolates. Results (Table 3) indicated that both INK-3 and
CP-51 gave dose-dependent activity against HIV-2, with
EC50 values of 0.21 and 0.32 µM and against TIBO-resis-
tant HIV-1 with EC50 values of 0.11 and 0.10 µM,
respectively. The EC50 values for INK-3 and CP-51 against
AZT-resistant HIV-1 clinical isolates (1073, 1074, G910,
G691) ranged from 0.12 to 0.90 µM and 0.19 to 0.64 µM,
respectively (Table 3). The EC50 values for AZT against
the same AZT-resistant HIV-1 clinical isolates ranged
from 0.03 to >2.5 µM (Table 3). Note that the EC50 for
AZT against a sensitive prototype HIV-1 strain was 0.009
µM (Table 2). Other results indicated that the PC lipid
INK-15 had no significant fold increase in EC50 between
the matched pairs of AZT-sensitive and AZT-resistant
HIV-1 clinical isolates (Table 4). However, the lipid–AZT
conjugate INK-14 and AZT alone showed a significant
fold increase in the EC50 ratio between the AZT-sensitive
and AZT-resistant HIV-1 clinical isolates of 23.4, 469 and
673.3, 75, respectively. In summary, the PC lipids INK-3
and CP-51 have potent activity against HIV-2 and TIBO-
and AZT-resistant HIV-1. There is no apparent cross-
resistance between PC lipid and TIBO or AZT
compounds. In contrast, the lipid–AZT conjugate (INK-
14) did show some cross-resistance with AZT.
Inhibition of fusogenic activity between 
persistently HIV-1-infected H9IIIB cells and
uninfected CD4+ CEM-SS cells
Published data from our laboratories indicated that CP-51
significantly inhibited HIV-1-induced fusogenic activity
(Krugner-Higby et al., 1995). In similar experiments (Table
5), results indicated that INK-3 also has significant dose-
dependent activity against HIV-1-induced fusogenic
activity. The EC50 values were 0.08, 0.18 and >1.0 µM for
INK-2, -3, and -1, respectively (Table 5). These results
suggest that selected PC lipid compounds active against
infectious HIV production (Table 2) also inhibited virus-
induced fusogenic activity.
Toxicity against mouse bone marrow cells as
compared to AZT
Two independent experiments were designed to compare
the relative toxicity of CP-51 and selected INK compounds
with AZT. Results of these studies indicated that INK-2,
-3 and -6 had a TC50 value of >100 µg/ml (Table 6). In two
experiments, the TC50 values for CP-51 were 9.15 and
14.17 µg/ml compared to 0.142 and 0.259 µg/ml for AZT
(Table 6). These data are interpreted to suggest that
selected PC lipid compounds are significantly less cytotoxic
than AZT to mouse bone marrow cells.
Discussion
Most of our previously synthesized alkylamidopropyl phos-
phocholines and alkoxy- and alkylthioglycerol
phosphocholines (PC lipids) were analogues of phos-
phatidylcholine and contained a long hydrocarbon chain
length (C16–C18) at position 1 and a short chain length
(C1–C2) at position 2 of the three carbon backbone. Many
of these compounds exhibited potent anti-HIV-1 activity.
The most promising analogue we have reported to date
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Table 3. Evaluation of PC lipids INK-3 and CP-51 and
AZT against TIBO-resistant, AZT-resistant HIV-1 and
wild-type HIV-2 measured by syncytial plaque assay
EC50 (µM)*
Compound TIBOr 1073 1074 G910 G691 HIV-2
INK-3 0.11 0.90 0.19 0.20 0.12 0.21
CP-51 0.10 0.19 0.20 0.64 0.33 0.32
AZT ND 0.16 0.03 >2.5 >2.5 ND
*EC50 values were calculated by the method of Chou and coworkers
(Chou & Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et
al. (1991).
Table 4. Evaluation of INK compounds for activity
against matched pairs of AZT-sensitive and 
AZT-resistant HIV-1 clinical isolates
EC50 (µM)
AZT-sensitive AZT-resistant 
strain strain Fold increase
Compound G-762 G-691 res./sen.
INK-14 0.10 2.34 23.4
INK-15 0.06 0.08 1.3
AZT 0.003 2.20 673.3
H112-2 G-910
INK-14 0.01 4.69 469
INK-15 0.07 0.02 <1
AZT 0.004 0.30 75
Assays were carried out using CEM-SS cells and the syncytial plaque
assay.
Abbreviations; res: resistant; sen: sensitive
(Kucera et al., 1990a) was 1-octadecanamido-2-
ethoxypropyl-3-phosphocholine (CP-51). This amidoalkyl
derivative exhibited an EC50 of 0.11 µM and a SI of 130
(Table 2). Accordingly, we chose this analogue as our lead
compound and proceeded to modify its structure to opti-
mize its anti-HIV-1 inhibitory activity and/or SI. In
addition, we wanted to ascertain whether a long hydro-
carbon chain length at position 1 was essential for optimum
anti-HIV-1 selectivity.
As seen from data in Table 2, numerous synthetic CP-
51 analogues including INK-2, INK-3, INK-6 and
INK-15 exhibited a higher SI than CP-51. The SI values
for these analogues in CEM-SS cells were 184.0, 298.9,
191.4 and 389.0, respectively, whereas their EC50 values
were comparable to that of CP-51. These results demon-
strated that a long hydrocarbon chain length of 16–18
carbons is not essential for optimum selectivity in this
series of PC compounds. Notably, data presented in Table
2 suggested that a shorter hydrocarbon chain length (Table
1) at position 1 (10 or 12 carbons) and a longer chain at
position 2 (12 or 8 carbons) as seen in INK-15 and INK-
3, respectively, improved the SI up to threefold (with a
concomitant decrease in cytotoxicity) compared with the
18 and 2 hydrocarbon chain lengths in CP-51.
Previously, we synthesized a series of alkyletherglycerol
phosphocholines (Meyer et al., 1991). Like the alkylamido
phosphocholine CP-51, these alkylether compounds had a
long hydrocarbon chain (C16–C18, oxy- or thioether) at
position 1 and a short chain (methoxy or ethoxy) at posi-
tion 2. The EC50 values for these alkylether
phosphocholines ranged from 0.3 to 1.4 µM and their SI
were lower (4 to 69) compared to that of CP-51 (130). In
view of the above data with the INK compounds, it was of
interest to synthesize an alkylether analogue of INK-2 to
determine whether the SI could be similarly improved in
this series. This alkylether analogue, INK-4, with oxyether
hydrocarbon chain lengths of 12 and 10 at the 1 and 2 posi-
tions, respectively, exhibited an EC50 of 0.64 µM, a TC50 of
75.7 µM, and a SI of 118.3. Notably, the TC50 value is
significantly different from that of any previously reported
alkylether phosphocholine (3 to 19 µM; Meyer et al.,
1991), again demonstrating that such hydrodrocarbon
chain length modifications will lead to a less cytotoxic
compound. In summary, these data indicated that hydro-
carbon chain lengths in the range of 10 to 12 at position 1
and 8 to 12 at position 2 should result in compounds with
less cytotoxicity than those with 16 to 18 hydrocarbon
chain lengths at position 1 and 1 to 2 at position 2.
Also, the TC50 values from PBL cells were comparable
to those from CEM-SS cells (Table 2). INK-13 and INK-
14, with 8 and 10 carbons at position 1 and 7 carbons at
position 2, respectively, were the least cytotoxic (TC50 ≥100
µM) compounds in the series. At the present time, no
specific experiments have been done to determine why
INK-13 and INK-14 were the least cytotoxic in the series
of compounds evaluated. In the case of the conjugate INK-
14, the hypothesis is that the lipid component acts as a
carrier for AZT. The lipid anchors the conjugate into the
cell membrane and is metabolized to slowly release lower
concentrations of AZT into cells compared to AZT treat-
ment alone. The end result is reduced toxicity from AZT.
Evidence in support of this hypothesis is the lower TC50
and higher SI for INK-14 compared to AZT (Table 2).
In the case of the phospholipid–AZT conjugates, INK-
14 [3′-azido-3′-deoxy-5′-(3-dodecylamido-2-octoxypro-
pyl)-phosphothymidine] and CP-92 [3′-azido-3′-deoxy-
5′-(3-octadecylamido-2-ethoxypropyl)-phosphothymidine]
had comparable SI values [>1250 (Table 2) and 1793
(Piantadosi et al., 1991), respectively]. Both compounds
had a higher SI than AZT alone (411, Table 2) and were
three- to fourfold more selective than AZT. In addition,
the cytotoxicity was lower; the TC50 for INK-14 was >100
µM in comparison to 3.7 µM for AZT.
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Table 5. Effect of PC lipid compounds on fusogenic
activity between persistently HIV-1-infected H9IIIB
cells and uninfected CD4+ CEM-SS cells
Inhibition of 










Persistently HIV-1-infected H9IIIB cells were treated with compound
for 96 h and cocultured with uninfected CD4+ CEM-SS cells (ratio 1 :
100) in the presence of added compound for 48 h. The number of
fused cells was counted relative to untreated control cells to deter-
mine the percentage inhibition of fusion and the IC50. The IC50
values were calculated by the method of Chou and coworkers
(Chou & Talalay, 1987; Johnson et al., 1989) as cited by Piantadosi et
al. (1991).
Table 6. In vitro cytotoxicity of PC lipid compounds
in CFU-GM assays
TC50 (µg/ml)






In control cultures treated with PBS there were 86 and 54
c.f.u./plate in Experiments 1 and 2, respectively.
The effects of lengthening the linkage between the
phosphate ester and the quaternary ammonium function-
ality were also studied through the synthesis of INK-8,
with three carbons separating the phosphate ester and the
quaternary nitrogen. This modification increased the EC50
and decreased the SI values (Table 2). At the present time,
it is difficult to draw any definitive conclusion relating to
such modification.
Based on these promising in vitro data, selected PC lipid
and lipid–AZT conjugates were further evaluated. The
results indicated that CP-51 and INK-3 also were active
against HIV-2 and TIBO-resistant HIV-1 (Table 3). We
also examined the effects of CP-51 and INK-3 against
AZT-resistant HIV-1 clinical isolates (1073, 1074, G910,
G691). As seen from the data in Table 3, both CP-51 and
INK-3 were markedly active against the AZT-resistant
mutants. Both the nucleoside analogue AZT and the non-
nucleoside TIBO analogue R82150 (nevirapine; White et
al., 1991) are known to inhibit HIV-1 RT (De Clercq,
1995). However, unlike AZT, which can also inhibit HIV-
2 RT activity, the non-nucleoside RT inhibitors do not
inhibit HIV-2 RT activity. This difference in antiviral spec-
trum may be due to the non-nucleoside analogue binding
at an allosteric site of RT, in contrast to the active site like
AZT (De Clercq, 1995). From our present data, PC lipids
are active against both TIBO- and AZT-resistant strains of
HIV-1, suggesting that PC lipids do not target the same
site(s) in the HIV replication cycle as compared to TIBO
derivatives and AZT.
Using matched pairs of AZT-sensitive and AZT-resis-
tant HIV-1 clinical isolates, results indicated that each pair
of isolates tested was similarly inhibited by the PC lipid
INK-15 (Table 4). These data are interpreted to suggest
that PC lipids do not show cross-resistance with AZT. In
contrast, these same pairs of clinical isolates did show
increased resistance to the conjugate compound INK-14
and to AZT alone (Table 4), suggesting that the most
active anti-HIV-1 component in the lipid–AZT conjugate
compound is probably AZT.
Results in Table 5 indicate that PC lipids were also
active in inhibiting fusogenic activity of HIV-1-infected
cells with uninfected cells. Recent published evidence by
other investigators (Feng et al., 1997) indicated that HIV-
1 enters cells via a co-receptor designated fusin (CXCR-4),
a member of the G protein-coupled chemokine receptor
family with seven member-spanning domains. McKnight
et al. (1997) reported that a monoclonal antibody to fusin
can block cell-to-cell fusion and cell-free virus infection of
fusin-positive CD4+ cells. Lipid analogues are known to
accumulate at the cell plasma membrane (Storme et al.,
1985; van Blitterswijk et al., 1987) and they serve as potent
inhibitors of HIV-1-induced cell fusion (Krugner-Higby et
al., 1995). This inhibition was correlated with inhibition of
gp160/gp120-specific monoclonal antibody with HIV-1
gp160/gp120 reactivity on the surface of HIV-1-infected
and treated cells (Krugner-Higby et al., 1995). It can be
speculated that the presence of lipid analogues could cause
steric hindrance of the CD4+ receptor and fusin co-receptor
in cell-to-cell fusion.
Published evidence indicates that the major antiviral
effect of recombinant interferon α (rIFN-α) operates in
the stages of virus assembly of gp120 and release (Hansen
et al., 1992; Smith et al., 1991; Willey et al., 1988).
Syntheses of HIV-1-induced DNA, RNA and protein
were minimally inhibited by rIFN-α but virus particles
released from the treated cells were 100- to 1000-fold less
infectious, owing to an assembly defect in gp120 (Hansen
et al., 1992). Our published data (Krugner-Higby et al.,
1995) indicated that anti-HIV PC lipids do not affect
HIV-1-induced protein synthesis and processing.
However, assembly of progeny virus particles made in the
presence of antiviral PC lipids was shifted from the plasma
membrane to intracytoplasmic vacuoles (Kucera et al.,
1990b), and this shift in assembly site was associated with
a profoundly reduced capacity of progeny virus particles to
bind to CD4+ cells (Krugner-Higby et al., 1995). Also, we
observed that exposure of fresh CD4+ cells to equivalent
amounts of RT activity associated with HIV-1 particles
from 1 µM PC lipid-treated cells resulted in a 40 to 68%
inhibition in subsequent HIV-1 replication compared to
HIV-1 particles from untreated control cells (LS Kucera, N
Iyer, SL Morris-Natschke, SY Chen, F Gumus, K Ishaq &
DBJ Herrmann, unpublished results). Data from Western
blot analysis of virus particles from PC lipid-treated cells
indicated that gp120 produced in infected cells was also
present in virus particles recovered from PC lipid-treated
cell supernatants (Krugner-Higby et al., 1995). Incubation
of PC lipid with preformed virions did not produce a viru-
cidal effect (LS Kucera, N Iyer, SL Morris-Natschke, SY
Chen, F Gumus, K Ishaq & DBJ Herrmann, unpublished
results). Krugner-Higby et al. (1995) showed that HIV
particles made in the presence of phospholipids had a
reduced capacity to bind to CD4+ cells. Taken together, our
data suggest that the reduced capacity of progeny virus
from PC lipid-treated cells to infect and replicate in fresh
CD4+ cells could be associated with an alteration in the
assembly of gp120 on the surface of progeny virus particles.
Thus, PC lipids may share a property in common with
rIFN-α by operating at the stage of HIV gp120 assembly
and release.
In summary, results from chemical synthesis and evalu-
ation of compounds for anti-HIV-1 activity in this present
investigation indicated that compounds with hydrocarbon
chain lengths of 10 to 12 at position 1 and 8 to 12 at posi-
tion 2 of a three carbon backbone have high SI against
HIV-1 replication. PC lipid analogues have potent and
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selective activity against HIV-1 and HIV-2 as well as
against TIBO- and AZT-resistant strains of HIV-1 and
virus-induced cell fusion. In view of the markedly reduced
toxicity of PC lipid analogues against bone marrow cell
growth in vitro compared to AZT, PC lipid analogues offer
an innovative approach toward development of novel
strategies for the treatment of HIV infections and AIDS.
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